PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Correction.

Abstract There was an error in our CPD article Chronic heart failure part 2: treatment and management (11 January). On page 55, the first sentence in the angiotensin receptor neprilysin inhibitor section should read: Valsartan with sacubitril is an angiotensin receptor neprilysin inhibitor that has recently been approved for use as a replacement for ACE inhibitors, to further reduce the risk of hospitalisation and death in ambulatory patients with heart failure and an ejection fraction ≤35% who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al 2016).
PMID
Related Publications

Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.

Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.

Authors
Mayor MeshTerms
Keywords
Journal Title nursing standard (royal college of nursing (great britain) : 1987)
Publication Year Start




PMID- 28176581
OWN - NLM
STAT- In-Data-Review
DA  - 20170208
LR  - 20170208
IS  - 2047-9018 (Electronic)
IS  - 0029-6570 (Linking)
VI  - 31
IP  - 24
DP  - 2017 Feb 08
TI  - Correction.
PG  - 30
LID - 10.7748/ns.31.24.30.s32 [doi]
AB  - There was an error in our CPD article Chronic heart failure part 2: treatment and
      management (11 January). On page 55, the first sentence in the angiotensin
      receptor neprilysin inhibitor section should read: Valsartan with sacubitril is
      an angiotensin receptor neprilysin inhibitor that has recently been approved for 
      use as a replacement for ACE inhibitors, to further reduce the risk of
      hospitalisation and death in ambulatory patients with heart failure and an
      ejection fraction </=35% who remain symptomatic despite optimal treatment with an
      ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al
      2016).
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nurs Stand
JT  - Nursing standard (Royal College of Nursing (Great Britain) : 1987)
JID - 9012906
EDAT- 2017/02/09 06:00
MHDA- 2017/02/09 06:00
CRDT- 2017/02/09 06:00
AID - 10.7748/ns.31.24.30.s32 [doi]
PST - ppublish
SO  - Nurs Stand. 2017 Feb 8;31(24):30. doi: 10.7748/ns.31.24.30.s32.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>